Methyl-CpG-binding protein 2 R294X mutant messenger RNA (MECP2 R294X mRNA)

Methyl-CpG-binding protein 2 (MECP2) R294X mutant messenger RNA (mRNA) is a specific transcript variant that serves as a therapeutic target for Rett syndrome, a severe neurodevelopmental disorder (PubMed: 18175354). The R294X mutation is a nonsense mutation (c.880C>T) that introduces a premature stop codon, resulting in a truncated protein that lacks the C-terminal domain necessary for proper function (UniProt: P51608). MECP2 is an essential epigenetic regulator that binds to methylated DNA and recruits co-repressor complexes to modulate gene expression in neurons; its deficiency disrupts synaptic maturation and maintenance. Therapeutic approaches targeting this mutant mRNA include nonsense suppression therapies, which use small molecules like ataluren or ELX-02 to encourage ribosomal read-through of the premature stop codon (PubMed: 22438870). Additionally, site-directed RNA editing technologies are being developed to chemically modify the mutant base within the mRNA transcript, such as using ADAR-mediated editing to convert the stop codon back into a coding sense (PubMed: 28530653). These strategies aim to restore endogenous levels of full-length MECP2 protein while avoiding the risks of gene over-dosage associated with traditional gene replacement therapies. Monitoring the efficacy of these treatments involves measuring the restoration of MECP2 protein and improvements in neurobehavioral biomarkers.

Other names

MECP2 c.880C>T mRNAMECP2 p.Arg294Ter mRNAMECP2 p.Arg294* mRNAMECP2 R294X transcript

Nonsense suppression (ribosomal read-through) or site-directed RNA editing to restore full-length protein translation.